Have a personal or library account? Click to login
Clinical Evolution of Patients with Schizophrenia Associated with Addictive Disorders Cover

Clinical Evolution of Patients with Schizophrenia Associated with Addictive Disorders

Open Access
|Dec 2020

References

  1. 1. Jablensky A. The diagnostic concept of schizophrenia: it’s history, evolution and future prospects. Dialogues in Clinical Neuroscience. 2010;12(3):271-287.10.31887/DCNS.2010.12.3/ajablensky
  2. 2. Warner R, De Girolamo G. Schizophrenia. Epidemiology of mental disorders and psychosocial problems. World Health Organization Geneva. 1995:1-6.
  3. 3. Nireștean A. Psychiatry Course. Tîrgu Mureș. 2005:92-98.
  4. 4. Lampe L, Malhi GS. Avoidant personality disorder. Current insights Psychology Behavioral Management. 2018;11:55–66.10.2147/PRBM.S121073
  5. 5. McGrath J, Saha S et al. Epidemiologic reviews. Oxford Academic. 2008;30(1):67-76.
  6. 6. Lieberman JA, Bowers J. Substance Abuse in Schizophrenia. Schizophrenia Bulletin. 1990;16(1):29-30.10.1093/schbul/16.1.29
  7. 7. Sinclair JMD, Zhao S, Fang Qi, Nyakyoma K, Kwong SWJ, Adams EC. Electroconvulsive therapy for treatment-resistant schizophrenia. Cochrane Database System Review. 2019;(3):CD01184-7.10.1002/14651858.CD011847.pub2
  8. 8. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders, Clinical descriptions and diagnostic guidelines; Geneva; 1992.
  9. 9. Lambert JRT, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. MJA. 2003;178:S67-S70.10.5694/j.1326-5377.2003.tb05311.x
  10. 10. Robert E, Mueser KT. Co-occuring alcohol use disorder and schizophrenia. Alcohol Research and Health. 2002;99-102.
  11. 11. Negrete JC, Tempier R. Drug and Alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophrenia Research. 2004;157-166.10.1016/S0920-9964(02)00523-6
  12. 12. Tsuang TM, Stone SW, Stephen V. Pharaoh-Genes, environment and Schizophrenia. British Journal of Psychiatry. 2001;178 (suppl40): 18-24.10.1192/bjp.178.40.s1811315219
  13. 13. Nielsen SM, Toftdahl NG, Nordentoft M. and Hjorthoj G. Association between alcohol, cannabis, and other illicit substance abuse and risk of developing schizophrenia: a nationwide population based register study. Psychol Med. 2017;47(9):1668-1677.10.1017/S003329171700016228166863
  14. 14. Lee R. Mistrustful and Misunderstood: A Review of Paranoid Personality Disorder. Current. Behaviour Neuroscience. 2017;4(2):151–165.
  15. 15. Correll CU, Schooler NR. Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment. Neuropsychiatry Disorders Treat. 2020;16:519–534.10.2147/NDT.S225643704143732110026
  16. 16. Maric PN, Jovicic MJ, Mihaljevic M, Mihaljevic C. Improving current treatments for schizophrenia. 2016;77(7):357-367.
  17. 17. Manea M, Manea MC, Puiu MG. Introduction to Psychiatry Volume I. Houston Publishing House. 2019;142-174;189-200.
  18. 18. Sagud M. Nicotine dependence in Croatian male inpatients with Schizophrenia. BMS Psychiatry. 2018;18-19.10.1186/s12888-018-1606-1577866029357830
  19. 19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5 th Edition.American Psychiatric Publishing. 2018;99-105, 481-570.
DOI: https://doi.org/10.2478/amma-2020-0033 | Journal eISSN: 2668-7763 | Journal ISSN: 2668-7755
Language: English
Page range: 152 - 154
Submitted on: Oct 30, 2020
Accepted on: Nov 24, 2020
Published on: Dec 31, 2020
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2020 Andreea Salcudean, Melinda Ferencz, Daniela Sabau, Madalina Gherman, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.